After Needham and William Blair gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price target of $39.00. The company’s shares closed last Monday at $26.91, close to its 52-week high of $27.97.
According to TipRanks.com, Yang ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.7% and a 38.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Nektar Therapeutics, and Akebia Therapeutics.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $34.00, representing a 27.8% upside. In a report issued on February 18, Piper Sandler also maintained a Buy rating on the stock with a $37.00 price target.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $45.33 million. In comparison, last year the company had a GAAP net loss of $40.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
Read More on RVNC:
